C25
Conditions
Interventions
Group 1: PDAC Stage 4
Sponsors
Klinikum der Universität München, Campus Großhadern
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: • signed informed consent • age =18 years • suspected metastatic pancreatic cancer to be the most likely diagnosis • clinical indication for a core biopsy of metastases • eligibility for one of the three chemotherapeutical regimens: G, G+nabP or FOLFIRINOX
Exclusion criteria
Exclusion criteria: • age <18 year • patient is unfit for chemotherapy • concurrent active cancer treatment at the time of screening • concurrent other active malignancy • contraindication for fine needle biopsy • pregnancy, breast feeding • conditions preventing structured follow-up within the boundaries of the study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The response to 1st and 2nd chemotherapy in comparison to response predicted by the RNA-based signatures using transcriptome data from fine needle biopsies of metastases of patients with stage IV PDAC. | — |
Secondary
| Measure | Time frame |
|---|---|
| i) The generation of a platform for simultaneous search for alternative treatments as rescue treatments once standard 1st and 2nd line treatments have failed, based on drug screening of patient derived organoids and identification of actionable mutations. ii) The feasibility to perform comprehensive IHC-multiplex analysis on fine needle biopsies of liver metastases. | — |
Countries
Germany
Contacts
Public ContactGeorg Beyer
Klinikum der Universität München, Campus Großhadern
Outcome results
None listed